Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
27.51 USD -0.94% Intraday chart for Supernus Pharmaceuticals, Inc. -5.46% -4.94%
May. 23 Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study MT
May. 23 Transcript : Supernus Pharmaceuticals, Inc. - Special Call

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
GL
Supernus Announces First Quarter 2024 Financial Results
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals : 2023 Annual Report
PU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
GL
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
PR
Supernus Provides Regulatory Update for SPN-830
GL
Supernus Provides Regulatory Update for SPN-830
AQ
Supernus to Participate in Two Upcoming Investor Conferences
GL
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
GL
Supernus: Q4 Earnings Snapshot
AQ
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
  5. Press Releases